Abstract: Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of SLC9A3R1 in the test cell sample or fluid sample as compared to the level of expression of SLC9A3R1 in a control cell sample or fluid sample isolated from a normal subject.

Abstract: Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of stratifin in the test cell sample or fluid sample as compared to the level of expression of stratifin in a control cell sample or fluid sample isolated from a normal subject.

Abstract: Disclosed are detergent-free protein extract buffers to extract proteins from formalin-fixed paraffin-embedded tissue sections, kit comprising the buffer, and methods for using the buffer to extract proteins from formalin-fixed, paraffin-embedded tissue sections.

Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.

Abstract: One implementation provides a computer-implemented method for modifying network configuration information on a client node. In this implementation, the client node establishes a first network connection with a host node using at least one network configuration parameter and collects configuration history information. The configuration history information includes at least one parameter that is related to the first network connection. The client node also analyzes policy information that includes a rule that is used for specifying a predetermined criterion. If one of the parameters in the configuration history information does not satisfy the predetermined criterion, the client node modifies one of the network configuration parameters. The client node is then capable of establishing a second network connection with the host node using the modified network configuration parameter.

Abstract: A computer-implemented system performs analysis on a construction material mixture includes accessing a server located on a wide-area-network; sending information collected from the material mixture to the server; applying one or more test methodologies to the collected information; generating one or more reports from the test methodologies; and sending the one or more reports to a project manager.

Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) protein on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin protein on the surface of a normal cell.

Abstract: Systems and methods are disclosed for designing and tracking construction material usage by estimating volumetric properties for one or more mix designs; determining an optimum mix based on laboratory data; and field testing a sample of the optimum mix; and tracking and managing construction material usage based on the optimum mix.

Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell.

Abstract: The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between HP-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (617EKGIYFKLVTM627, (SEQ ID NO: 1) 658SRSSLIRKRSTRRSVRGSQA677 (SEQ ID NO: 2) and 694PVSFWRIMKLNLT706 (SEQ ID NO: 3) for HP-gp1 and 618LMKKEGVYFKLVNM631 (SEQ ID NO: 4), 648KAATRMAPNGWKSRLFRHSTQKNLKNS674 (SEQ ID NO: 5), and 695PVSFLKVLKLNKT707 (SEQ ID NO: 6) for HP-gp3) in linker domains bound to proteins with apparent molecular masses of ˜80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized.

Abstract: Systems and methods are disclosed for designing and tracking construction material usage by estimating volumetric properties for one or more mix designs; determining an optimum mix based on laboratory data; and field testing a sample of the optimum mix; and tracking and managing construction material usage based on the optimum mix.

Abstract: Methods are disclosed for diagnosing chemotherapeutic drug resistance in neoplastic cells by detecting an increase in the expression of calumenin in such neoplastic cells as compared to the level of expression of calumenin protein in a non-MDR neoplastic cell. In addition, disclosed are methods for treating neoplastic cells, including reversing or preventing chemotherapeutic drug resistance, by increasing the sensitivity of the neoplastic cells to a chemotherapeutic drug.

Abstract: Disclosed are methods for diagnosing cancer in a cell sample by detecting an increase in the levels of expression of marker genes in the cell sample as compared to the levels of expression of the same marker genes in a normal, nonneoplastic cell of the same tissue type. Also disclosed is a focused microarray device for diagnosis of cancer in a cell sample.

Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.

Abstract: Disclosed are methods for treating neoplastic cells, including reversing or preventing chemotherapeutic drug resistance, by increasing the sensitivity of the neoplastic cells to a chemotherapeutic drug. In addition, methods are further disclosed for diagnosing chemotherapeutic drug resistance in neoplastic cells by detecting an increase in the expression of prohibitin in such neoplastic cells as compared to the level of expression of prohibitin protein in a non-MDR neoplastic cell.

Abstract: Disclosed are methods for treating and/or preventing neoplasms in a patient by contacting the neoplasm with therapeutic agents capable of binding, hybridizing, or interacting with proteins on the cell surface of neoplastic cells. In addition, therapeutic compositions are disclosed for the treatment and/or prevention of a neoplasm in a patient in need thereof.

Abstract: Disclosed are methods for diagnosing ovarian cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic ovarian cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.

Abstract: Systems and methods are disclosed for asphalt mix design by predicting properties associated with a mix of volumetric properties; verifying properties of the mix by digitally collecting data for each gyration from a gyratory compactor; selecting an optimum mix based on the gyration data; determining a percentage of maximum theoretical density; testing properties of the optimum mix with an ignition process; and determining gradation of the optimum mix.

Abstract: Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.

Abstract: Disclosed are methods for detecting a neoplasm and/or chemotherapeutic drug resistance or angiogenic potential in neoplastic cells by detecting an increase in the expression of ?-enolase in such cells, or in the case of metastatic potential on the surface of such cells, as compared to the level of expression of ?-enolase protein in a normal or non-MDR neoplastic cell or on the surface of a non-metastatic neoplastic cell. In addition, methods and a composition are disclosed for increasing the sensitivity of a neoplasm to a chemotherapeutic drug treatment regime, for inhibiting angiogenesis and metastatic potential in chemotherapeutic drug resistant or neoplastic cells, and for inducing apoptosis in chemotherapeutic drug resistant or neoplastic cells.